8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
SEC · EDGAR 财务披露 · November 9, 2026 at 7:33 AM ET
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 9, 2026
VIRIDIAN THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36483 | 47-1187261 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 221 Crescent Street, Suite 103A Waltham, MA |
02453 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (617) 272-4600
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
| Common Stock, $0.01 par value | VRDN | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 | Regulation FD Disclosure |
On November 9, 2026, Viridian Therapeutics, Inc. (the “Company”) issued a press release announcing data from a phase 1 clinical trial of VRDN-008, a half-life extended bispecific FcRn inhibitor, in healthy volunteers. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 7.01 and in Exhibit 99.1 to this Current Report on Form 8-K is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Exchange Act of 1934 or the Securities Act of 1933, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
| Item 8.01 | Other Events |
On November 9, 2026, the Company announced positive results of a phase 1 clinical trial in healthy volunteers of VRDN-008, a half-life extended bifunctional FcRn inhibitor, which the Company believes supports a potential best-in-class FcRn-inhibitor profile with every-eight-week (“Q8W”) subcutaneous dosing.
In the trial, VRDN-008 demonstrated deep and sustained Immunoglobin G (“IgG”) reduction through eight weeks after subcutaneous dosing in six healthy volunteers, with 74% reduction at peak. VRDN-008 demonstrated an extended half-life of 15 to 18 days, five to six times longer than the half-life of the first-generation Fc fragments. VRDN-008 also demonstrated a safety profile that spared albumin and low-density lipoprotein and was generally well tolerated. Pharmacokinetic modeling with VRDN-008 phase 1 clinical data demonstrated levels of IgG reduction that support advancing subcutaneous Q8W and every-four-week (“Q4W”) dose regimens into registrational development. The Company plans to initiate at least one pivotal clinical trial in 2027, starting with myasthenia gravis (“MG”) in mid-2027, pending regulatory feedback. The Company plans to administer VRDN-008 via enFuse® in a multi-arm clinical trial in MG testing Q4W and Q8W dosing versus placebo to support a direct-to-registrational development path, pending regulatory feedback.
The Company currently plans to focus its clinical development efforts related to its FcRn inhibitor portfolio on the further advancement of VRDN-008. The Company may pursue opportunities related to the development of VRDN-006 in the future.
This Current Report on Form 8-K contains forward-looking statements, including, without limitation, statements regarding VRDN-008’s potential best-in-class FcRn-inhibitor profile and dosing regimen, the Company’s plans to initiate at least one pivotal clinical trial in 2027, starting with MG in mid-2027, pending regulatory feedback, and the Company’s expectation of a direct-to-registrational development path for VRDN-008. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on the Company’s current beliefs, expectations, and assumptions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties, including, but not limited to, risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those risks set forth under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 4, 2026, and other subsequent disclosure documents filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the Company nor any of its affiliates, advisors or representatives undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| 99.1 | Press Release, dated November 9, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Viridian Therapeutics, Inc. | ||||||
| Date: November 9, 2026 | By: | /s/ Stephen Mahoney | ||||
| Stephen Mahoney | ||||||
| President and Chief Executive Officer | ||||||